预约演示
更新于：2025-02-24
Torsemide
托拉塞米
更新于：2025-02-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
56
项与 托拉塞米 相关的临床试验NCT06708611
A Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide Over 12 Hours After Dosing in Patients With Heart Failure (EXTOR-HF)
NCT06176794
A Crossover Study of Patients With Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide vs. Extended Release Torsemide Over 12 Hours After Dosing
CTRI/2024/09/073919
Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,396
项与 托拉塞米 相关的文献（医药）2025-04-01INTERNATIONAL JOURNAL OF CANCER
Cyclin‐dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database
Article
作者: Cao, Weihang ; Jin, Pengfei ; Li, Ting ; Zhao, Ming ; Li, Shaoqiang ; Kou, Chen ; Huang, Jing ; Zhang, Tian ; Zhang, Miaomiao
Abstract:
Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation. However, studies on the link between CDK4/6 inhibitors and cardiotoxic events show inconsistent results, and the factors influencing these events and related drug interactions remain underexplored. To address these uncertainties, our study utilizes the FDA adverse event reporting system database (Q1 2015 to Q1 2024) to examine the cardiotoxic events of CDK4/6 inhibitors in breast cancer patients. We employed a comprehensive analytical framework, applying disproportionality methods including Bayesian confidence propagation neural network, proportional reporting ratio, and reporting odds ratio. Our findings highlight significant variability in cardiotoxic events among different CDK4/6 inhibitors, with ribociclib (IC: 0.26, 95%CI: 0.18–0.34) exhibiting pronounced cardiotoxicity. Notably, ribociclib was associated with serious cardiotoxic events such as torsade de pointes/QT prolongation (IC: 2.11, 95% CI: 1.90–2.29) and conduction defects (IC: 2.07, 95% CI: 1.87–2.23). For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter. Moreover, multivariable logistic regression and Bayesian network analyses reveal that age, geographic location, and the number of concomitant medications significantly influence cardiotoxic events. Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.
2025-03-01JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
Torsemide can be used for long-term management of congestive heart failure in equids: a description of 12 cases (2019–2024)
Article
作者: Shroff, Kavita ; Stefanovski, Darko ; Kraus, Marc S. ; Solis, Cristobal Navas de ; Reef, Virginia B.
Abstract:
OBJECTIVE:
Information about congestive heart failure (CHF) treatment in the horse is limited. Torsemide, an oral loop diuretic, is increasingly used in humans, dogs, and cats with CHF. Torsemide is well absorbed and induces diuresis in healthy horses, and its use in a horse with CHF has been reported. This retrospective descriptive study aimed to describe the use of torsemide in equids with CHF.
ANIMALS:
12 equids (10 horses, 1 miniature donkey, and 1 mule).
CLINICAL PRESENTATION:
Horses presented to a referral practice with clinical signs of congestive heart failure. Diagnosis was confirmed with echocardiography. Treatment with torsemide as well as other cardiac medications was instituted. The cases were evaluated and monitored with physical examinations, clinicopathologic data, and repeat echocardiograms.
RESULTS:
Torsemide (PO, q 12 h [median 0.5 mg/kg; IQR, 0.5 to 0.5 mg/kg; range, 0.25 to 1 mg/kg]) was well tolerated in the 12 cases. There were improvements in heart rate and respiratory rate and increases in plasma creatinine concentration (median, 1.3 vs 1.9 mg/dL) that followed therapeutic interventions that included torsemide. Median survival time of equids with CHF treated with torsemide was 189 days (IQR, 10 to 348.25 days; range, 2 to 806 days), with 2 distinct clusters. Four cases were euthanized within 2 weeks after starting treatment, while 8 survived longer than 137 days or are currently alive.
CLINICAL RELEVANCE:
Torsemide can be used in equids diagnosed with CHF without serious adverse events and has the potential to be a useful oral diuretic. The nature of the study does not allow us to conclude that torsemide had a causal relationship with clinical progression.
2025-02-01ESC Heart Failure
Prevalence and characteristics of upfront diuretic resistance in acute heart failure: The P‐Value‐AHF study
Article
作者: Huber, Lars C. ; Bellasi, Antonio ; Lupi, Eleonora ; Cippà, Pietro E. ; Baumberger, Julia ; Wolters, Thomas ; Arrigo, Mattia ; Dinges, Sabine ; Stüssi‐Helbling, Melina
Abstract:
Aims:
Diuretic resistance (i.e., insufficient diuretic and natriuretic response to an appropriate dose of intravenously administered loop diuretic) is a major cause of insufficient decongestion in acute heart failure (AHF). Early assessment of diuretic and natriuretic response already after the first administration of loop diuretic is currently recommended, but few data exist on the prevalence and characteristics of upfront diuretic resistance in AHF. The aim of this sub‐study of the P‐Value‐AHF randomized clinical trial was to investigate the prevalence and characteristics of upfront diuretic resistance in patients presenting with AHF in the emergency department (ED).
Methods:
Consecutive patients presenting with a clinical diagnosis of AHF, ≥1 sign of congestion, and NT‐proBNP >1000 ng/L between February and June 2024 were prospectively screened. Loop diuretics were administered per protocol: 40 mg furosemide i.v. in diuretic‐naïve patients and those on oral torasemide <40 mg, 80 mg furosemide i.v. in patients on oral torasemide ≥40 mg daily. Urine output was measured over the following 2 h and in patients with urine volume <300 mL, urine sodium concentration was additionally measured in a spot sample. Upfront diuretic resistance was defined as urine volume <300 mL in 2 h and urine sodium concentration <70 mmol/L.
Results:
From a total of 127 screened AHF patients presenting to the ED, 17 subjects were excluded after denial of informed consent and 17 could not be treated according to the protocol due to one or more exclusion criteria. Of the remaining 93 per‐protocol‐treated patients, 91 showed an adequate diuretic response either in terms of urine volume or urine sodium concentration. Only two of 93 patients (2.2%) met the criteria of upfront diuretic resistance. In a post‐hoc analysis, patients with diuretic resistance had higher prevalence of chronic kidney or liver diseases, markedly lower blood pressure and heart rate, markedly higher serum creatinine and potassium levels, and lower serum sodium. Notably, clinical signs of congestion, circulating NT‐proBNP, and left‐ventricular ejection fraction were similar in both groups.
Conclusions:
Upfront diuretic resistance in an unselected population of AHF patients presenting to the ED affects only a minority of patients. These data highlight the importance of a standardized, protocolized approach to decongestive treatment in AHF, which includes the rapid administration of loop diuretics in an adequate dose. Pre‐existing chronic kidney disease and high creatinine levels were more prevalent in patients with diuretic resistance.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-01 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-01 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-01 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 蓋夢範餘廠齋衊糧廠繭(壓夢餘醖簾製製蓋獵膚) = 繭獵壓鹹廠築鏇選構蓋 衊憲範製糧獵觸範夢鹽 (鹹廠衊積糧廠獵範遞鑰, 構積夢築醖觸憲糧鹽夢 ~ 鬱鏇築選簾窪壓憲窪築) 更多 | - | 2024-10-15 | ||
(Torsemide) | 蓋夢範餘廠齋衊糧廠繭(壓夢餘醖簾製製蓋獵膚) = 艱製顧糧壓醖繭蓋糧顧 衊憲範製糧獵觸範夢鹽 (鹹廠衊積糧廠獵範遞鑰, 積構願築窪窪顧夢襯鑰 ~ 鏇鏇鏇蓋夢餘壓衊醖選) 更多 | ||||||
临床3期 | 88 | 憲願鏇構製齋襯鑰窪淵(網顧廠築網壓簾鹽襯鏇) = 鏇遞窪製遞鑰齋糧夢醖 淵鬱壓願鏇鹽遞願選醖 (醖築艱鑰選糧夢鬱選築, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
憲願鏇構製齋襯鑰窪淵(網顧廠築網壓簾鹽襯鏇) = 鹹餘窪廠蓋齋醖鬱糧衊 淵鬱壓願鏇鹽遞願選醖 (醖築艱鑰選糧夢鬱選築, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 遞鹹壓繭築艱顧鏇糧憲(簾願範鑰選觸願餘窪壓) = 鹹壓醖選鏇簾簾遞鏇構 壓醖衊蓋夢築願獵淵餘 (壓蓋窪積製夢構餘衊選 ) 更多 | 不佳 | 2024-05-15 | |||
遞鹹壓繭築艱顧鏇糧憲(簾願範鑰選觸願餘窪壓) = 範鬱鑰膚鏇願蓋製襯構 壓醖衊蓋夢築願獵淵餘 (壓蓋窪積製夢構餘衊選 ) 更多 | |||||||
N/A | - | - | 壓構顧齋醖選遞鹹醖憲(廠蓋鹹淵蓋壓醖壓壓觸) = low blood pressure 簾範憲積壓齋鑰鏇網鏇 (構壓願獵網範鏇淵鬱鑰 ) 更多 | - | 2024-05-13 | ||
临床2期 | 118 | (Torsemide) | 憲獵積淵鏇艱鹹蓋夢壓(糧齋糧夢選鹹壓膚廠衊) = 蓋憲選餘顧觸製觸築鑰 襯膚鏇淵糧鏇餘遞廠鏇 (糧繭願糧膚遞壓膚範構, 製網膚壓範憲願鬱簾壓 ~ 鏇糧淵壓窪鹽積夢廠構) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 憲獵積淵鏇艱鹹蓋夢壓(糧齋糧夢選鹹壓膚廠衊) = 積艱鏇糧夢繭壓醖築膚 襯膚鏇淵糧鏇餘遞廠鏇 (糧繭願糧膚遞壓膚範構, 餘網顧築齋簾製壓選網 ~ 選鹽壓壓觸鏇顧膚糧膚) 更多 | ||||||
N/A | - | 襯蓋遞願鹽觸窪餘積簾(簾窪積壓觸襯夢積積鏇) = 網廠衊衊製餘繭鹹艱糧 艱鹽壓膚鬱糧糧鏇艱憲 (築鹽襯壓醖憲餘鑰範網 ) | - | 2017-08-29 | |||
襯蓋遞願鹽觸窪餘積簾(簾窪積壓觸襯夢積積鏇) = 製醖製糧網廠願鬱糧窪 艱鹽壓膚鬱糧糧鏇艱憲 (築鹽襯壓醖憲餘鑰範網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用